LAVA Therapeutics (NASDAQ:LVTX) Short Interest Down 69.8% in September

LAVA Therapeutics (NASDAQ:LVTX) was the target of a significant decrease in short interest in September. As of September 30th, there was short interest totalling 9,800 shares, a decrease of 69.8% from the September 15th total of 32,500 shares. Based on an average daily volume of 58,300 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.1% of the company’s stock are short sold.

Institutional Trading of LAVA Therapeutics

A hedge fund recently bought a new stake in LAVA Therapeutics stock. Pathway Financial Advisors LLC acquired a new stake in shares of LAVA Therapeutics (NASDAQ:LVTX) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 14,000 shares of the company’s stock, valued at approximately $47,000.

LAVA Therapeutics Stock Performance

LAVA Therapeutics stock remained flat at $1.60 during mid-day trading on Thursday. The company’s stock had a trading volume of 18,059 shares, compared to its average volume of 627,935. LAVA Therapeutics has a twelve month low of $1.13 and a twelve month high of $6.47. The company has a quick ratio of 6.39, a current ratio of 6.39 and a debt-to-equity ratio of 0.01. The business has a 50 day simple moving average of $1.74 and a 200 day simple moving average of $2.25. The company has a market capitalization of $40.56 million, a P/E ratio of -1.48 and a beta of 0.51.

LAVA Therapeutics (NASDAQ:LVTX) last released its quarterly earnings data on Tuesday, August 20th. The company reported ($0.31) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.05. LAVA Therapeutics had a negative net margin of 228.02% and a negative return on equity of 48.53%. Equities research analysts anticipate that LAVA Therapeutics will post -1.28 EPS for the current year.

Analyst Ratings Changes

LVTX has been the topic of a number of recent research reports. HC Wainwright reaffirmed a “buy” rating and issued a $6.00 target price on shares of LAVA Therapeutics in a research report on Friday, June 28th. JMP Securities restated a “market outperform” rating and issued a $6.00 price objective on shares of LAVA Therapeutics in a report on Wednesday, August 21st.

LAVA Therapeutics Company Profile

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.